Human Pharmacokinetics and Safety Profile of Finafloxacin, a New Fluoroquinolone Antibiotic, in Healthy Volunteers
暂无分享,去创建一个
H. Labischinski | A. Vente | M. Seiberling | H. Heilmann | H. Patel | W. Stubbings | R. Pokorny | A. Andresen | L. López-Lázaro
[1] S. Schubert,et al. Comparative In Vitro Activities of the Novel Antibacterial Finafloxacin against Selected Gram-Positive and Gram-Negative Bacteria Tested in Mueller-Hinton Broth and Synthetic Urine , 2011, Antimicrobial Agents and Chemotherapy.
[2] K. Naber,et al. Urinary Pharmacokinetics and Bactericidal Activity of Finafloxacin (200 and 800 mg) in Healthy Volunteers Receiving a Single Oral Dose , 2008, Chemotherapy.
[3] A. Dalhoff. Comparative Inhibitory and Bactericidal Activities of Finafloxacin (FIN) and Ciprofloxacin (CIP) against Gram-Negative and Gram-Positive UTI-pathogens Under Physiological Conditions and at Varying pH-values , 2008 .
[4] R. Endermann. Pharmacokinetics (PK) and In Vivo Efficacy of Oral Finafloxacin (FIN) and Comparators in Rodent Models of Systemic Infection , 2008 .
[5] R. Endermann. In Vivo Efficacy of Finafloxacin (FIN) in Difficult to Treat Animal Models of Infection , 2008 .
[6] W. Stubbings. Bactericidal Activity Of Finafloxacin (FIN) Against Difficult To Kill Growth Forms Of Escherichia coli , 2008 .
[7] H. Patel. A Phase I Study to Determine Safety, Tolerability and Pharmacokinetics (PK) of Finafloxacin (FIN) in Healthy Subjects , 2008 .
[8] M. Kresken. Effect of pH on the In Vitro Activity of Finafloxacin against Gram-negative and Gram-positive Bacteria , 2008 .
[9] W. Stubbings. Antimicrobial Activity of Finafloxacin (FIN) against Helicobacter pylori In Vitro and In Vivo , 2008 .
[10] K. Kerr. Quinolone Antimicrobial Agents. 3rd Ed. , 2004, Journal of Clinical Pathology.
[11] F. Schmitz,et al. In Vitro Antibacterial Activity and Pharmacodynamics of New Quinolones , 2003, European Journal of Clinical Microbiology and Infectious Diseases.
[12] H. Stass,et al. Pharmacokinetics, Safety, and Tolerability of Ascending Single Doses of Moxifloxacin, a New 8-Methoxy Quinolone, Administered to Healthy Subjects , 1998, Antimicrobial Agents and Chemotherapy.
[13] S. Chien,et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses , 1997, Antimicrobial agents and chemotherapy.
[14] D. Hooper,et al. Quinolone antimicrobial agents , 1993 .
[15] P. Welling,et al. Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers , 1984, Antimicrobial Agents and Chemotherapy.